Story perspectives

Wegovy Gains FDA Approval for MASH Treatment

8/18/2025

42 5

Summary

Story summary

Wegovy by Novo Nordisk received FDA accelerated approval for treating metabolic dysfunction-associated steatohepatitis (MASH) in adults with liver fibrosis.
The approval follows positive ESSENCE trial results, indicating significant liver health improvements.
Wegovy is now available in the U.S., alongside Madrigal Pharmaceuticals' Rezdiffra as approved MASH treatments.
MASH impacts approximately 5% of U.S. adults and poses serious health risks if untreated.

1 of 1

Story summary

Wegovy by Novo Nordisk received FDA accelerated approval for treating metabolic dysfunction-associated steatohepatitis (MASH) in adults with liver fibrosis.
The approval follows positive ESSENCE trial results, indicating significant liver health improvements.
Wegovy is now available in the U.S., alongside Madrigal Pharmaceuticals' Rezdiffra as approved MASH treatments.
MASH impacts approximately 5% of U.S. adults and poses serious health risks if untreated.